Citius Oncology IncCTOR
Price$0.98

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $5.6MTTM through 30 Jun 2026
Net Income -$46.1MTTM through 30 Jun 2026
Free Cash Flow -$14.3MTTM through 30 Jun 2026

Margins

Current
Gross Margin80.3%
Operating Margin-1,609.8%
Net Margin-1,596.0%

Returns

-91.1%ROE
-31.9%ROA

Balance Sheet Health

Debt / Equity0.11x
Current Ratio0.50x
Net Debt$1.2M
Cash & Equivalents$16.6M

Quality Metrics

Altman Z-Score-1.88
Piotroski F-Score2 / 9
FCF Margin-255.0%
Earnings-Beat Rate25.0%

Multi-Year Trend

Diluted EPS-$0.48TTM
'22'23'23'24'25
FY2025: $-0.34

Dividend

No dividend

Capital Allocation

R&D Spend$3.4M
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.